Sporos Bioventures, LLC is a private biotechnology company focused on transforming the drug development process across oncology.
Sporos Bioventures owns equity interests in several biopharma entities: Tvardi Therapeutics, Asylia Therapeutics, and Sporos BioDiscovery.
Sporos Bioventures operates two of its affiliate portfolio companies including Sporos BioDiscovery, which is home to a pipeline of wholly-owned preclinical assets, and Asylia Therapeutics. In addition, Sporos Bioventures has established multiple asset teams within its structure that intently focus on R&D and draw from Sporos’ central infrastructure and subject matter experts.
Learn more about our portfolio companies.Learn More
Understanding cancer genetics and biology is key to designing potent and targeted therapies that provide maximal anticancer activity.
Targeted approaches to cancer treatment can see strong patient responses, but often have limited durability because of cancer’s uncanny ability to evade the immune system by harnessing new mechanisms for survival and regrowth.
Using a genetically-validated framework, Sporos generates key biological insights into tumor-specific vulnerabilities and their symbiotic interactions across the broader tumor microenvironment. This approach provides a FULL picture of each cancer and how to develop therapeutic candidates that may improve outcomes and quality of life for patients.